Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925923 · ClinicalTrials.gov registry record · Phase 2
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02925923 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 100 participants.
The verdict
NCT02925923, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at the time of percutaneous coronary intervention (PCI). This suggests that faster platelet inhibition with crushed ticagrelor , eptifibatide , or cangrelor is needed to reduce HPR and periprocedural myocardial infarction and injury (PMI). The present study compared the effects of crushed ticagrelor vs. eptifibatide bolus + clopidogrel in troponin-negative ACS patients undergoing PCI.
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
- DRUG Eptifibatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2018-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02925923
The ClinicalTrials.gov registry entry for NCT02925923 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clopidogrel is the first listed.
NCT02925923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02925923 about?
NCT02925923 is a clinical study titled "Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel". Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at the time of percutaneous coronary intervention (PCI). This suggests tha...
What is the current status of trial NCT02925923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-11-01. Estimated completion is 2018-12-01.
What interventions are being tested in trial NCT02925923?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG), Eptifibatide (DRUG).
Who is sponsoring clinical trial NCT02925923?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.